High tides: Long-term data ready Takeda for bringing first dengue travel vaccine to market Alnylam stays on Calliditas’ heels as Regeneron-partnered nephropathy drug passes phase 2 Back in the Frame: CureVac inks biotech buyout to step up cancer vaccine R&D Sponsored: Tech-Enabled Trials Don't Have to Mean Loss of Human Connection ASCO: Takeda Oncology ready to stoke partnerships to fire up cancer-fighting pillar technologies Betting on both types of CAR-T, Tessa grabs $126M series A to push assets through clinic Roche's bispecific blood cancer drug Lunsumio treads on CAR-T's turf with first global approval Astellas opens new $100M gene therapy production plant Foundation Medicine's tumor test scores yet another companion diagnostic nod, for Genentech's Rozlytrek LA County's tentative labor deal heads off 1,300-physician strike at 3 public hospitals 'Runaway train': Drug launch prices have grown 20% annually for more than a decade, and it's time for Congress to act, researchers say To address training gap, NYU College of Nursing will offer course on LGBTQ+ healthcare Featured Story | By James Waldron New long-term data from Takeda’s TIDES study of its dengue fever vaccine provide the missing piece of the puzzle in the Japanese pharma’s quest to bring the first travel shot for the infection to market. read more |
| |
|---|
|
Top Stories By Max Bayer Alnylam has reached a phase 2 checkpoint of its Regeneron-partnered immunoglobulin A nephropathy treatment as it looks to catch up with Calliditas Therapeutics' FDA-approved med Tarpeyo. read more By Nick Paul Taylor CureVac, bruised from its COVID-19 vaccine woes, has struck another deal to bolster its cancer vaccine development capabilities, buying Frame Cancer Therapeutics for its ability to identify unique and shared neoantigens. read more Sponsored by: Vault Health DCTs hold the promise of reducing site and patient burdens but at what cost to human connection? Vault says it doesn't have to be a compromise. read more By Gabrielle Masson Takeda Oncology employees arrived on the scene at the American Society of Clinical Oncology meeting eager to be back in person and ready to talk potential partnerships that could bolster the Japanese pharma's three main “pillar” areas. read more By James Waldron Anticipating the challenges in CAR-T therapy development, Singapore’s Tessa Therapeutics has hedged its bets by developing two different types of the anticancer drug and will now use proceeds from a $126 million series A funding round to push its assets through clinical trials. read more By Angus Liu After Rituxan's fall off the patent cliff, Roche is looking to new assets to replenish its blood cancer arsenal. With a first-in-class nod, the Swiss pharma is introducing a novel bispecific lymphoma drug that will first compete with powerful CAR-T therapies. read more By Joseph Keenan Japan’s Astellas Pharma completed construction of a $100 million gene therapy manufacturing plant located in Sanford, North Carolina. read more By Andrea Park Foundation Medicine’s flagship cancer diagnostic is designed to detect substitutions and alterations in more than 300 genes—and the company seemingly won’t rest until the test has been cleared for use alongside just as many cancer drugs. read more By Dave Muoio The deal was proposed Friday night after “intensive bargaining” that kicked off on Wednesday, the LA County Committee of Interns and Residents said. read more By Eric Sagonowsky With plenty of U.S. residents having to make tough financial decisions daily because of inflation, a new study confirms what many have likely been feeling for years: Drug prices are much, much higher than in the past. read more By Anastassia Gliadkovskaya Students will learn about LGBTQ+ health issues, regulations and addressing discrimination. read more Resources Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored By: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA @Philly Cell and Gene Therapy Annual Conference 2022 June 17-18th 2022; King of Prussia, PA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 